Hypoxia-Inducible Factor 1-alpha (HIF1α), Nicotinamide Adenine Dinucleotide (NAD+, NADH), and Nitric Oxide (NO) interplay in critically ill patients, with implications for patient safety and targeted therapies: a review.

backgroundCritical illnesses such as sepsis, trauma, and multi-organ failure initiate complex molecular cascades that disrupt cellular homeostasis and contribute to poor outcomes. Key among these mediators are Nicotinamide Adenine Dinucleotide (NAD+/NADH), Nitric Oxide (NO), and Hypoxia-Inducible Factor 1-alpha (HIF1α), each playing crucial roles in redox regulation, immune modulation, and tissue adaptation to hypoxia. REVIEW: This review examines the individual and interrelated roles of NAD+, NO, and HIF1α in critically ill patients. We explore how imbalances in NAD+/NADH ratio impair mitochondrial metabolism, how dysregulated NO signaling alters vascular tone and immune responses, and how HIF1α stabilization governs transcriptional programs under hypoxia. By mapping the biochemical crosstalk among these molecules, we identify potential feedback loops that influence inflammation, cellular energetics, and patient outcomes. A central theme is the safety and therapeutic relevance of modulating these mediators, with specific focus on the timing, context, and molecular profile of patients in critical care.

conclusionUnderstanding the dynamic interplay among NAD+, NO, and HIF1α offers new opportunities for precision medicine in critical illness. We propose a hypothesis that phase-specific modulation of these pathways—through NAD+ precursors, NO donors/scavengers, or HIF1α stabilizers—could improve outcomes if guided by real-time molecular profiling. Prioritizing patient safety through targeted, biomarker-informed interventions may prevent progression to multi-organ failure and enable more personalized and effective treatments.